European Commission Approves Pluvicto for PSMA-Positive mCRPC

OncLive, Dec 14, 2022

The European Commission has approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto™; formerly 177Lu-PSMA-617) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy.

The approval follows a positive opinion issued in October by the European Medicines Agency’s Committee for Medicinal Products for Human Useand is applicable to all 27 European Union member states plus Iceland, Norway, Northern Ireland, and Liechtenstein.

>> Read the article